Business
Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy
Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical
About this update from Cardiff Oncology, Inc.
[{"type":"text","content":"Pancreatic Cancer Program\n- Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical controls with ORR of 19% (vs. 7.7%) and mPFS of 5.0 months (vs. 3.1 months) -\n- Pancreatic cancer biomarker discovery trial in refractory patients demonstrated tumor biomarker response to onvansertib treatment as a single-agent -\n- Based on positive data from both pancreatic trials and supportive preclinical data, a first-line pancreatic investigator-initiated trial is planned to evaluate the efficacy of onvansertib + SoC -\nSmall Cell Lung Cancer Program\n- Preliminary data from small cell lung cancer Phase 2 trial in refractory patients with extensive stage disease demonstrate single-agent activity from onvansertib monotherapy -\n- Company will hold a conference call today at 5:00 p.m. ET/2:00 p.m. PT -\nSAN DIEGO, Sept. 26, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced positive clinical data with onvansertib monotherapy and combination therapy in our ongoing trials in metastatic pancreatic ductal adenocarcinoma (mPDAC) and small cell lung cancer (SCLC), as well as plans for a mPDAC first-line investigator-initiated trial (IIT) of the combination of onvansertib plus standard-of-care (SoC).\n\"We are excited that the data released from these trials, in two challenging cancers with low survival rates, expands the opportunity for onvansertib beyond our lead program in RAS-mutated mCRC,\" said Mark Erlander, Ph.D., Chief Executive Officer of Cardiff Oncology. \"In pancreatic cancer, the strength of the data provides a clear rationale for a first-line trial using onvansertib in combination with standard of care, which we believe provides the greatest opportunity for a positive impact on patients. In small cell lung cancer, we are encouraged to observe single-agent activity with onvansertib monotherapy in this difficult-to-treat extensive stage refractory setting.\"\nmPDAC Phase 2 CRDF-001 trial: 19% ORR and 5.0-month mPFS \nData from the ongoing Phase 2 open-label trial of onvansertib combined with nanoliposomal irinotecan, leucovorin, and 5-FU in patients with second-line mPDAC demonstrated an objective response rate (ORR) of 19% ...